Back to Search Start Over

A pooled testing strategy for identifying SARS-CoV-2 at low prevalence

Authors :
Mutesa, Leon
Ndishimye, Pacifique
Butera, Yvan
Souopgui, Jacob
Uwineza, Annette
Rutayisire, Robert
Ndoricimpaye, Ella Larissa
Musoni, Emile
Rujeni, Nadine
Nyatanyi, Thierry
Ntagwabira, Edouard
Semakula, Muhammed
Musanabaganwa, Clarisse
Nyamwasa, Daniel
Ndashimye, Maurice
Ujeneza, Eva
Mwikarago, Ivan Emile
Muvunyi, Claude Mambo
Mazarati, Jean Baptiste
Nsanzimana, Sabin
Turok, Neil
Ndifon, Wilfred
Source :
Nature; January 2021, Vol. 589 Issue: 7841 p276-280, 5p
Publication Year :
2021

Abstract

Suppressing infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will probably require the rapid identification and isolation of individuals infected with the virus on an ongoing basis. Reverse-transcription polymerase chain reaction (RT–PCR) tests are accurate but costly, which makes the regular testing of every individual expensive. These costs are a challenge for all countries around the world, but particularly for low-to-middle-income countries. Cost reductions can be achieved by pooling (or combining) subsamples and testing them in groups1–7. A balance must be struck between increasing the group size and retaining test sensitivity, as sample dilution increases the likelihood of false-negative test results for individuals with a low viral load in the sampled region at the time of the test8. Similarly, minimizing the number of tests to reduce costs must be balanced against minimizing the time that testing takes, to reduce the spread of the infection. Here we propose an algorithm for pooling subsamples based on the geometry of a hypercube that, at low prevalence, accurately identifies individuals infected with SARS-CoV-2 in a small number of tests and few rounds of testing. We discuss the optimal group size and explain why, given the highly infectious nature of the disease, largely parallel searches are preferred. We report proof-of-concept experiments in which a positive subsample was detected even when diluted 100-fold with negative subsamples (compared with 30–48-fold dilutions described in previous studies9–11). We quantify the loss of sensitivity due to dilution and discuss how it may be mitigated by the frequent re-testing of groups, for example. With the use of these methods, the cost of mass testing could be reduced by a large factor. At low prevalence, the costs decrease in rough proportion to the prevalence. Field trials of our approach are under way in Rwanda and South Africa. The use of group testing on a massive scale to monitor infection rates closely and continually in a population, along with the rapid and effective isolation of people with SARS-CoV-2 infections, provides a promising pathway towards the long-term control of coronavirus disease 2019 (COVID-19).

Details

Language :
English
ISSN :
00280836 and 14764687
Volume :
589
Issue :
7841
Database :
Supplemental Index
Journal :
Nature
Publication Type :
Periodical
Accession number :
ejs54708872
Full Text :
https://doi.org/10.1038/s41586-020-2885-5